1. Home
  2. PKOH vs CHRS Comparison

PKOH vs CHRS Comparison

Compare PKOH & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park-Ohio Holdings Corp.

PKOH

Park-Ohio Holdings Corp.

HOLD

Current Price

$29.78

Market Cap

299.5M

Sector

Industrials

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.78

Market Cap

296.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PKOH
CHRS
Founded
1907
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
299.5M
296.8M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
PKOH
CHRS
Price
$29.78
$1.78
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$37.00
$5.51
AVG Volume (30 Days)
46.8K
927.7K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
1.69%
N/A
EPS Growth
N/A
472.00
EPS
1.70
1.43
Revenue
$1,599,100,000.00
N/A
Revenue This Year
$7.87
$73.08
Revenue Next Year
$3.42
$30.94
P/E Ratio
$17.07
$1.21
Revenue Growth
N/A
N/A
52 Week Low
$15.52
$0.72
52 Week High
$30.45
$2.62

Technical Indicators

Market Signals
Indicator
PKOH
CHRS
Relative Strength Index (RSI) 64.13 51.44
Support Level $19.21 $1.55
Resistance Level N/A $1.89
Average True Range (ATR) 1.51 0.10
MACD 0.19 -0.01
Stochastic Oscillator 80.86 31.82

Price Performance

Historical Comparison
PKOH
CHRS

About PKOH Park-Ohio Holdings Corp.

Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: